Fennec Pharmaceuticals shares were down after the company reported fourth-quarter results. The stock was recently down 10% to $6.20 and is down about 2% this year. Revenue declined to $7.93 ...

However, for productivity use, it easily outperforms the other two Zen 5 X3D chips, and anything offered by Intel for that matter. AMD Ryzen 9 9950X3D Review by Jacqueline Thomas "The AMD Ryzen 9 ...

Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings and Corporate Update Conference Call. At this time, all participants are in a ...

Fennec Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.06 EPS, expectations were $0.56. Operator: Good morning, ladies and gentlemen, and welcome to Fennec ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2024 and provided a business update ...

Early Repayment of $13 Million of the Company’s Approximately $32 Million Outstanding Convertible Debt Facility: In December 2024, Fennec announced the early partial repayment of a significant ...

In recent months, processor technology has significantly improved with the introduction of AMD’s Ryzen 9000 series. The Ryzen 9000 series presents a next-generation architecture that emphasizes ...

After hours: March 24 at 5:14:03 PM EDT Loading Chart for FENC ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Fennec Pharmaceuticals Inc (FENC) reports a 40% revenue increase and successful PEDMARK launches in Europe, while navigating competitive challenges and operational expenses.